Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25649310 | 1.00 | BTK (0.53) | BTK | |
| SCHEMBL30497654 | 0.97 | BTK (0.50) | BTK | |
| SCHEMBL25277091 | 0.93 | BTK (0.54) | BTK | |
| SCHEMBL31684280 | 0.91 | BTK (0.48) | BTK | |
| SCHEMBL21966564 | 0.91 | BTK (0.48) | BTK | |
| SCHEMBL21965636 | 0.91 | BTK (0.48) | BTK | |
| SCHEMBL31684282 | 0.91 | BTK (0.48) | BTK | |
| SCHEMBL30449342 | 0.91 | BTK (0.50) | BTK | |
| SCHEMBL25649311 | 0.91 | BTK (0.50) | BTK | |
| SCHEMBL21965243 | 0.89 | BTK (0.44) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110970-A1 | MACROCYCLIC BTK INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.